Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500434 · ClinicalTrials.gov registry record · Phase 3
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT01500434 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 102 participants.
The verdict
NCT01500434, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions can be longer than average-sized.
Interventions
- DRUG Aspirin
- DEVICE PROMUS Element Coronary Stent System
- DRUG Thienopyridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01500434
The ClinicalTrials.gov registry entry for NCT01500434 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Aspirin is the first listed.
NCT01500434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01500434 about?
NCT01500434 is a clinical study titled "The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)". The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions can be longer than average-sized.
What is the current status of trial NCT01500434?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2009-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01500434?
The interventions under investigation include: Aspirin (DRUG), PROMUS Element Coronary Stent System (DEVICE), Thienopyridine (DRUG).
Who is sponsoring clinical trial NCT01500434?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.